

# Paolo Prandoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3010456/publications.pdf>

Version: 2024-02-01

95  
papers

9,283  
citations

126907

33  
h-index

45317

90  
g-index

96  
all docs

96  
docs citations

96  
times ranked

6084  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Long-Term Clinical Course of Acute Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 1996, 125, 1.	3.9	1,818
2	The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <i>Haematologica</i> , 2007, 92, 199-205.	3.5	686
3	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	27.0	577
4	Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome. <i>Annals of Internal Medicine</i> , 2004, 141, 249.	3.9	575
5	An Association between Atherosclerosis and Venous Thrombosis. <i>New England Journal of Medicine</i> , 2003, 348, 1435-1441.	27.0	574
6	Cancer and venous thromboembolism. <i>Lancet Oncology</i> , The, 2005, 6, 401-410.	10.7	525
7	Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2002, 137, 955.	3.9	457
8	The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. <i>Circulation</i> , 2014, 130, 1636-1661.	1.6	446
9	Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. <i>Lancet</i> , The, 2007, 370, 1773-1779.	13.7	354
10	Editor's Choice "European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 9-82.	1.5	308
11	Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. <i>New England Journal of Medicine</i> , 2010, 363, 1222-1232.	27.0	301
12	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	2.2	267
13	Aspirin for the Prevention of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 130, 1062-1071.	1.6	232
14	Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. <i>New England Journal of Medicine</i> , 2016, 375, 1524-1531.	27.0	181
15	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018, 118, 214-224.	3.4	160
16	Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparin in the Initial Treatment of Venous Thromboembolism. <i>Archives of Internal Medicine</i> , 2004, 164, 1077.	3.8	108
17	Contrast Venography, the Gold Standard for the Diagnosis of Deep-Vein Thrombosis: Improvement in Observer Agreement. <i>Thrombosis and Haemostasis</i> , 1992, 67, 08-12.	3.4	107
18	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 172-179.	3.4	97

#	ARTICLE	IF	CITATIONS
19	Endothelial dysfunction in patients with spontaneous venous thromboembolism. <i>Haematologica</i> , 2007, 92, 812-818.	3.5	92
20	The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 133-140.	2.7	79
21	Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. <i>Cancer Medicine</i> , 2017, 6, 1165-1172.	2.8	76
22	Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. <i>Lancet Haematology</i> , 2018, 5, e25-e33.	4.6	72
23	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	5.2	71
24	Duration of anticoagulation after venous thromboembolism in real world clinical practice. <i>Thrombosis Research</i> , 2015, 135, 666-672.	1.7	62
25	Antithrombotic Strategies in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 1997, 78, 141-144.	3.4	61
26	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014, 12, 25.	2.1	55
27	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 733-738.	3.4	55
28	Cancer, thrombosis and heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2007, 120, S137-S140.	1.7	53
29	How I treat venous thromboembolism in patients with cancer. <i>Blood</i> , 2005, 106, 4027-4033.	1.4	46
30	Antiphospholipid Antibodies, Recurrent Thromboembolism, and Intensity of Warfarin Anticoagulation. <i>Thrombosis and Haemostasis</i> , 1996, 75, 859-859.	3.4	43
31	Comparison of Real-Time B-Mode Ultrasonography and Doppler Ultrasound with Contrast Venography in the Diagnosis of Venous Thrombosis in Symptomatic Outpatients. <i>Thrombosis and Haemostasis</i> , 1993, 70, 404-407.	3.4	42
32	Residual vein thrombosis and trans-popliteal reflux in patients with and without the postthrombotic syndrome. <i>Thrombosis and Haemostasis</i> , 2013, 110, 854-855.	3.4	38
33	Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. <i>British Journal of Haematology</i> , 2008, 141, 587-597.	2.5	36
34	A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2018, 165, 107-111.	1.7	35
35	Acquired Risk Factors for Venous Thromboembolism in Medical Patients. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 458-461.	2.5	32
36	Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. <i>Thrombosis Research</i> , 2017, 153, 97-100.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 773-777.	4.1	28
38	The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. <i>Internal and Emergency Medicine</i> , 2020, 15, 447-452.	2.0	28
39	Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2017, 12, 1291-1305.	2.0	23
40	Controversies in the management of cancer-associated thrombosis. <i>Expert Review of Hematology</i> , 2017, 10, 15-22.	2.2	23
41	Optimal duration of anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1210-1215.	3.4	21
42	Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. <i>Thrombosis Research</i> , 2015, 136, 917-923.	1.7	21
43	Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 320-328.	3.4	21
44	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015, 44, e377-e383.	1.9	20
45	Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations. <i>Thrombosis Research</i> , 2014, 134, 227-233.	1.7	19
46	The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: New scenarios and opportunities. <i>European Journal of Internal Medicine</i> , 2014, 25, 25-30.	2.2	18
47	Fondaparinux in the initial and long-term treatment of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 135, 311-317.	1.7	18
48	Is there a link between venous and arterial thrombosis? A reappraisal. <i>Internal and Emergency Medicine</i> , 2020, 15, 33-36.	2.0	17
49	Deep Vein Thrombosis and Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 1991, 66, 426-429.	3.4	17
50	Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. <i>Thrombosis Research</i> , 2016, 141, 91-92.	1.7	15
51	Post-thrombotic syndrome. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 331-340.	1.4	15
52	Venous Thromboembolism and Arterial Complications. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 205-210.	2.1	14
53	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	1.7	14
54	Risk and prognosis of cancer after upper-extremity deep venous thrombosis: A population-based cohort study. <i>Thrombosis Research</i> , 2018, 161, 106-110.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Recurrent Thromboembolism in Cancer Patients: Incidence and Risk Factors. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 003-008.	2.7	12
56	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	1.7	11
57	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. <i>TH Open</i> , 2020, 04, e446-e456.	1.4	11
58	Thrombosis as a harbinger of cancer. <i>Current Opinion in Hematology</i> , 2006, 13, 362-365.	2.5	10
59	The advent of the novel oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2014, 11, 70-72.	13.7	10
60	Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux. <i>Haematologica</i> , 2022, 107, 303-306.	3.5	10
61	Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism: Evidence From Major Clinical Trials. <i>Seminars in Hematology</i> , 2014, 51, 121-130.	3.4	9
62	Residual vein thrombosis and the risk of subsequent serious complications. <i>Thrombosis Research</i> , 2015, 136, 178-179.	1.7	9
63	An association between residual vein thrombosis and subclinical atherosclerosis: Cross-sectional study. <i>Thrombosis Research</i> , 2017, 157, 16-19.	1.7	9
64	Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 124, 1059-1063.	1.6	8
65	The impact of deep vein thrombosis on the risk of subsequent cardiovascular events: a 14-year follow-up study. <i>International Angiology</i> , 2017, 36, 156-159.	0.9	7
66	The Treatment of Venous Thromboembolism in Patients with Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 123-135.	1.6	6
67	Inter-observer variability of compression ultrasound for the assessment of residual vein thrombosis. <i>Thrombosis Research</i> , 2016, 145, 1-2.	1.7	6
68	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, 016950.	1.9	6
69	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 997-1003.	2.0	6
70	New Strategies for the Treatment of Acute Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 787-792.	2.7	5
71	What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 799-807.	1.8	4
72	Incidence of Arterial Embolism in Patients on Treatment with Old and New Anticoagulants for Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 154-159.	2.7	4

#	ARTICLE	IF	CITATIONS
73	The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2391-2394.	1.8	4
74	High rate of inter-observer agreement between professional-rated scores of the Villalta scale for the assessment of the post-thrombotic syndrome. <i>Thrombosis Research</i> , 2016, 144, 182-183.	1.7	4
75	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	1.7	4
76	No difference in outcome between therapeutic and preventive anticoagulation in patients with superficial vein thrombosis involving the saphenous-femoral junction. <i>Vascular Medicine</i> , 2022, 27, 290-292.	1.5	4
77	Should cancer patients receive thromboprophylaxis to prevent catheter-related upper limb deep vein thrombosis?. <i>Internal and Emergency Medicine</i> , 2008, 3, 85-86.	2.0	3
78	Thromboprophylaxis in Medical Inpatients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, e11.	1.5	3
79	Pregnancy-related venous thromboembolism and risk of occult cancer. <i>Blood Advances</i> , 2017, 1, 2059-2062.	5.2	3
80	Optimal duration of anticoagulation in patients with unprovoked venous thromboembolism: the impact of novel anticoagulants. <i>International Angiology</i> , 2017, 36, 395-401.	0.9	3
81	Determinants of severe post-thrombotic syndrome: The role of thrombus location. <i>Thrombosis Research</i> , 2019, 178, 171-172.	1.7	3
82	Emerging strategies for treatment of venous thromboembolism. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 87-94.	2.4	2
83	The optimal long-term treatment of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 729-32.	0.3	2
84	The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. <i>Advances in Experimental Medicine and Biology</i> , 2016, 906, 89-100.	1.6	1
85	An unusual finding of massive pulmonary embolism in a patient during treatment with high-dose ibuprofen. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 167-168.	2.9	1
86	Trans-popliteal reflux in limbs with and without deep-vein thrombosis of the same subject: Cross-sectional study. <i>Thrombosis Research</i> , 2017, 154, 53-54.	1.7	1
87	Low reproducibility of the diagnosis of subsegmental pulmonary embolism in symptomatic patients. <i>Thrombosis Research</i> , 2019, 175, 6-7.	1.7	1
88	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019, 104, e474-e477.	3.5	1
89	Confirmation of the Failure of Computerized Impedance Plethysmography in the Diagnostic Management of Patients with Clinically Suspected Deep-Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1991, 66, 744-744.	3.4	1
90	Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolism. <i>The Journal of Supportive Oncology</i> , 2006, 4, 127-8.	2.3	1

#	ARTICLE	IF	CITATIONS
91	The Natural History of Venous Thromboembolism. , 0, , 27-52.		0
92	Does the presence of clinical symptoms of pulmonary embolism affect the outcome of patients with deep vein thrombosis?. Thrombosis Research, 2017, 157, 134-135.	1.7	0
93	On the questionable ethics of randomizing patients with acute DVT to receive rivaroxaban or warfarin. Surgery, 2020, 167, 515.	1.9	0
94	Edoxaban for the Longâ€Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0
95	New perspectives for prevention of the post-thrombotic syndrome. , 2022, 1, 24-28.		0